We feed better futures
Results Presentation 1Q26
280k+
Global team members
250+
Production facilities
~200
Sales to customers
in ~200 countries
#1 POULTRY
#1 BEEF
#2 PORK
PREPARED
#1
FOODS
Global poultry producer
Market leader in Brazil and Europe.
Leading position in the USA and Mexico.
Global beef producer
Market leader in Australia, Brazil, and the USA. Leading position in Canada.
Global pork producer
Leading positions in Australia, Brazil, Europe and the USA.
Market leader in Australia, New Zealand and the UK. Leading positions in Brazil, Mexico and the USA.
#1
PLANT-
BASED
Plant-based foods
producer in Brazil.
#2 in Europe.
#2 SALMON
Salmon producer
in Australia.
#1 EGGS
Table Egg producer in South America.
BIOTECHNOLOGY
Majority owner of BioTech Foods,
cultivated protein producer in Spain.
Built largest biotechnology
3
R&D center in Brazil.
Net Revenues
US$ billion
88.3
[Brazil Margarine & Mayonnaise]
65.0
86.2
72.6
72.9
77.2
¹
[Beef]
51.2
48.9
49.0
51.1
49.7
51.7 52.3
[Eggs]
36.9
38.6
42.9
31.1
[Meats & Meals]
16.5
17.6
7.6
[Brazil & Mexico Chicken]
2.0
[United Kingdom]
[Pork]
2006 2007 2008 2009 2010 2011 2012 2013 2014 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 1Q26
LTM
6.7
7.2
6.8
6.4
4.7
4.0
4.2
5.0
5.6
2.1
3.3
4.0
3.5
1.9
2.2
2.8
0.3 0.3
0.7
0.6
8.5
Established a Global Protein Platform
Increased Diversification Into Value-Added and Branded Product Portfolios
Source: JBS
Note: (1) 50% control.
Valued Added: Diversified Global Brands Portfolio
Net revenue LTM 1Q26
(by production)
Canada
5%
USA
51%
Europe
6%
Protein production in competitively advantageous locations with scale
Diversification by protein and by geography
Mexico
2%
Brazil
26%
Oceania
10%
Source: JBS.
Beef Pork Lamb Poultry AquaculturePrepared
based
Foods
Leather Plant-Center for
Innovation
Cultivated
Protein
Eggs
Net revenue LTM 1Q26
Canada
4%
USA
50%
Export access and unmatched distribution platform
Positioned to mitigate geopolitical, sanitary and cyclical risks
Mexico & Central America
5%
South America
1%
(by consumption)
Europe
9%
Brazil
12%
Africa &
Middle East
3%
Australia & New Zealand
3%
Asia
13%
Source: JBS.
Team members
in the USA and Canada
79K
Team members in Mexico
13K
15
Team
17K
Team members in Europe
4K
members
1K
Team members
in MENA
in Brazil 16K
Team members in Australia and New Zealand
Source: JBS.
2008 - 2012
2013 - 2017
2018 - 2022
2023 - LTM 1Q26
Key Developments
Adjusted EBITDA Margin Evolution
Initial geographic and protein diversification, with relevant beef and pork acquisitions in the US
Initial focus on downstream diversification, with value-added prepared foods and brand positioning, driving margin expansion
JBS has evolved into a more profitable global player with a robust protein portfolio and vast footprint
2012
2013
2014
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025 LTM 1Q26
2011
2010
2009
2008
JBS Brazil
JBS Australia
Consolidated
Seara
JBS Beef North America
JBS USA Pork
PPC
7.3%
Median: 9.7%
Median: 8.2%
Median: 5.1%
Source: JBS.
Presence on the U.S and Brazilian Stock
Exchanges
Shares traded on the NYSE since June 13, 2025
Potential unlocking of the value of
company's shares.
Broaden access to a wider base of investors
Reduce the cost of capital both equity and debt
Increase flexibility to use equity as source
of funding
Increase the number of equity indexes in which JBS can participate (Russell, S&P, MSCI USA, among others)
Expand conditions of growth
10
1
USA
Walker County (Georgia): New Pilgrim's prepared foods facility
Ankeny (Iowa): Fully cooked bacon and sausage facility
Perry (Iowa): Fresh sausage plant
Cactus (Texas) and Greeley (Colorado): Modernization of beef processing plants
USA
Mantiqueira acquired Hickman's, creating the 3rd largest egg producer in the world
2 1
3
9
2 3
Mexico
Pilgrim's announced investments in Mexico in prepared and fresh foods
4
5
6
8
Europe
Vivera acquired The Vegetarian Butcher in 2025 from Unilever
7
4 5
Saudi Arabia
Investment in a new facility in Jeddah, and expansion of the plant in Dammam
6
Oman
Develop a multiprotein platform in Oman
The JV will produce beef, poultry and lamb, serving the global halal market
Paraguay
Investments in poultry production, including the acquisition of Pollos Amanecer
9
Brazil
Investments in innovation and modernization of three biodiesel plants
8 7
Vietnam
JBS announced the construction of two factories
Source: JBS
Legend:
Beef Pork
Poultry
Lamb
Eggs
Prepared Foods
Plant-based
Biodiesel 11
12
Results
Consolidated Results
Net Revenue
(US$ million)
21,609
Net Result
(US$ million)
ROE & ROIC (LTM)
19,527
0.47
500
0
0.21
221
24.1% 22.1%
18.0% 14.9%
1Q25 1Q26
1Q25 1Q26
1Q25 1Q26
ROE ROIC
Earnings per share
Source: JBS.
Consolidated Results
Operating Cash Flow
(US$ million)
Free Cash Flow
(US$ million)
CAPEX
(US$ million)
566
56%
-285
-449
-917
-1,467
Expansion Maintenance
265
44%
30 %
70 %
1Q25 1Q26
1Q25 1Q26
1Q25 1Q26
Source: JBS.
Consolidated Results
IFRS - US$ million
7.8%
Adjusted EBITDA
1,528
5.2%
1,133
1Q25
1Q26
Margin %
5.1%
2.4%
Adj. Operating Income
992
516
1Q25
1Q26
Margin %
US GAAP - US$ million
6.7%
Adjusted EBITDA
1,312
4.2%
916
1Q25
1Q26
Margin %
5.1%
Adj. Operating Income
999
1Q25
2.5%
544
1Q26
Margin %
Source: JBS.
Proforma Debt Profile
6,928
500
6,907
500
Proforma Debt Amortization Schedule (US$ million)
Average Term Proforma: 15.6 yrs Average Cost Proforma: 5.7% p.a.
2,925
2,500
1,071
1,450
2,925
2,930 2,318 1,140
2,416
3,503 3,482
840
236 116
649 157
1,369
1,2281,416 1,693
442
883 959
1,235
1,000
984
403
Cash and Equiv.
Bonds Tender Offer
+ Div.
Cash and Equiv. Proforma
Short Term
2027 2028 2029 2030 2031 2032 2033 2034 2035 2036 2037 2038
to 2051
2052 2053 2055 2056 2057 2065 2066
Full Investment Grade
Cash and equivalents
Notes 2037
& 2057
Revolving credit lines US$ 2.9 billion in the US + US$ 500 million in Brazil
Tender of US$250 million in the 2033 PPC Notes and US$ 1.2 billion in the 2034 Notes
Dividend Payment¹
(1) Dividends to be paid in June, 2026.
Source: JBS.
Debt Profile
Net Debt/ Leverage / Interest Coverage
7.75x 7.74x
6.84x 6.50x
5.75x
17,862
1.99x 2.27x 2.39x 2.39x 2.77x
14,752
16,524
16,611
16,320
1Q25 2Q25 3Q25 4Q25 1Q26
Net Debt (US$ millions) Interest Cover. (US$) Leverage (US$)
Short Term and Long Term Source Breakdown
Entity Breakdown
Source: JBS.
LT 96%
Bonds Banks
85% 3%
CRA
ST 12%
4%
JBS USA
87% JBS SA
6%
Seara 7%
Net Debt Reconciliation
16,320
1,233 183 341
566 111 218 122
(47) (52)
(US$ million)
17,862
(1,133)
2.39x
2.77x
Net debt | Adjusted | Working | Biological | Interest Paid | CAPEX | Lease | Taxes | Exchange Rate | Non | Other¹ | Net debt |
4Q25 | EBITDA | Capital | Assets | and Received | Payments | Variaton | recurring | 1Q26 | |||
+Margin Cash | |||||||||||
+Derivatives |
¹Considering acquisitions, non-cash items and Others.
Source: JBS.
Solid FCF Generation Supporting Investments, Distributions to Shareholders and Deleveraging
Capital Deployment Profile (USS mn)
Net Leverage (Net Debt/EBITDA in x)
Total
2019-1Q26
Average 2019-1Q26
4.75x
Free Cash Flow (Excl. Expansion Capex) | 14,5G7 | 2,013 |
4.50x
4.25x
4.00x
3.75x
Expansion Capex | 6,063 | 836 |
MsA | 3,451 | 476 |
3.50x
3.25x
3.00x
2.75x
2.50x
2.25x
2.00x
Dividends2 | 6,3G1 | 882 |
Share Buybacks | 3,35G | 463 |
Change in Net Debt1 | 4,667 | 644 |
1.75x
1.50x
1.25x
2.13x
1.58x
1.44x
2.24x
4.42x
M&A Limit
Cap on Dividend
Payment
Attention Zone
Safety Zone 2.77x 2.3Gx
1.8Gx
Long-Term Goal
Source: JBS
Note:(1) Net debt change includes FX and other non-cash adjustments; (2) Considering the payment that will occur in June in the total amount of US$1.071 billion
1.00x
201G 2020 2021 2022 2023 2024 2025 1Q26
Interest Coverage
2019 2020 2021 2022 2023 2024 2025 1Q26 LTM
6.2x 7.8x 11.6x 8.0x 3.2x 7.4x 6.5x 5.7x
Free Cash Flow
USD mn | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 1Q26 LTM |
Adjusted EBITDA1 | 5,015 | 5,637 | 8,486 | 6,722 | 3,458 | 7,192 | 6,831 | 6,437 |
Capex | (1,076) | (1,145) | (1,781) | (2,173) | (1,502) | (1,480) | (2,099) | (2,401) |
Expansion (572) | (607) | (989) | (1,195) | (733) | (509) | (1,139) | (1,379) | |
Maintenance (504) | (538) | (792) | (977) | (769) | (971) | (961) | (1,022) | |
Interest Expenses | (848) | (630) | (687) | (794) | (1,101) | (1,295) | (1,114) | (1,185) |
Leasing | (344) | (306) | (360) | (434) | (429) | (418) | (433) | (445) |
Working Capital | 154 | 536 | (1,245) | (1,235) | 617 | (327) | (852) | (812) |
Biological Assets | (427) | (532) | (724) | (865) | (529) | (521) | (821) | (812) |
Taxes | (546) | (629) | (1,124) | (1,039) | (72) | (349) | (809) | (793) |
Non-recurring | - | - | (763) | (167) | (90) | (171) | (403) | (216) |
Other non-cash adjustments2 | 91 | 41 | 56 | (44) | 96 | (300) | 99 | 78 |
Free Cash Flow | 2,020 | 2,972 | 1,858 | (30) | 448 | 2,332 | 400 | (149) |
Source: JBS.
1 Adjusted EBITDA excluding non-recurring items and in IFRS; 2 Such as fair value (market to market) of biological assets, among others.
| Attention: This is an excerpt of the original content. To continue reading it, access the original document here. |
